{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:12:25Z","timestamp":1793916745588,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T00:00:00Z","timestamp":1532736000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"International Science and Technology Cooperation Projects","award":["2015DFA30650 and 2016YFE0107100"],"award-info":[{"award-number":["2015DFA30650 and 2016YFE0107100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4651-8","type":"journal-article","created":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T07:32:57Z","timestamp":1532763177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression"],"prefix":"10.1186","volume":"18","author":[{"given":"Jianzhen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueshuai","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingci","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,28]]},"reference":[{"issue":"10","key":"4651_CR1","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1002\/ijc.25421","volume":"127","author":"E Bertran","year":"2010","unstructured":"Bertran E, Heise K, Andia ME, Ferreccio C. Gallbladder cancer: incidence and survival in a high-risk area of Chile. Int J Cancer. 2010;127(10):2446\u201354.","journal-title":"Int J Cancer"},{"issue":"1","key":"4651_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"4651_CR3","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1093\/annonc\/mdt204","volume":"24","author":"S Schlesinger","year":"2013","unstructured":"Schlesinger S, Aleksandrova K, Pischon T, Jenab M, Fedirko V, Trepo E, Overvad K, Roswall N, Tjonneland A, Boutron-Ruault MC, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol. 2013;24(9):2449\u201355.","journal-title":"Ann Oncol"},{"issue":"2","key":"4651_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.suc.2014.01.009","volume":"94","author":"JA Wernberg","year":"2014","unstructured":"Wernberg JA, Lucarelli DD. Gallbladder cancer. Surg Clin North Am. 2014;94(2):343\u201360.","journal-title":"Surg Clin North Am"},{"issue":"6","key":"4651_CR5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1572-0241.2000.02070.x","volume":"95","author":"S Sheth","year":"2000","unstructured":"Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 2000;95(6):1402\u201310.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4651_CR6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/000313481508100623","volume":"81","author":"M Ercan","year":"2015","unstructured":"Ercan M, Bostanci EB, Cakir T, Karaman K, Ozer I, Ulas M, Dalgic T, Ozogul Y, Aksoy E, Akoglu M. The rationality of resectional surgery and palliative interventions in the management of patients with gallbladder cancer. Am Surg. 2015;81(6):591\u20139.","journal-title":"Am Surg"},{"issue":"4","key":"4651_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell"},{"issue":"26","key":"4651_CR8","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"1","key":"4651_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"10088","key":"4651_CR10","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim T-Y, Choo S-P, Trojan J, Welling TH, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"issue":"13","key":"4651_CR11","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015\u201329.","journal-title":"J Exp Med"},{"issue":"3","key":"4651_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261\u20138.","journal-title":"Nat Immunol"},{"issue":"12","key":"4651_CR13","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","volume":"23","author":"JH Yearley","year":"2017","unstructured":"Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in Cancer. Clin Cancer Res. 2017;23(12):3158\u201367.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4651_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4161\/onci.1.1.18075","volume":"1","author":"Y Hirohashi","year":"2012","unstructured":"Hirohashi Y, Torigoe T, Inoda S, Morita R, Kochin V, Sato N. Cytotoxic T lymphocytes: sniping cancer stem cells. Oncoimmunology. 2012;1(1):123\u20135.","journal-title":"Oncoimmunology"},{"issue":"131","key":"4651_CR15","first-page":"574","volume":"61","author":"S Jiang","year":"2014","unstructured":"Jiang S, Pei L, Yang ZL, Liu G. Prognostic value of the stem cell markers Epcam and CD133 expression of gallbladder adenocarcinoma. Hepato-Gastroenterology. 2014;61(131):574\u20139.","journal-title":"Hepato-Gastroenterology"},{"issue":"2","key":"4651_CR16","first-page":"181","volume":"310","author":"Z Ai","year":"2011","unstructured":"Ai Z, Pan H, Suo T, Lv C, Wang Y, Tong S, Liu H. Arsenic oxide targets stem cell marker CD133\/prominin-1 in gallbladder carcinoma. Cancer Lett. 2011;310(2):181\u20137.","journal-title":"Cancer Lett"},{"issue":"2","key":"4651_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"6","key":"4651_CR18","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/hep.28710","volume":"64","author":"J Calderaro","year":"2016","unstructured":"Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay D, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology. 2016;64(6):2038\u201346.","journal-title":"Hepatology"},{"issue":"18","key":"4651_CR19","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","volume":"25","author":"Q Gao","year":"2007","unstructured":"Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586\u201393.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4651_CR20","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1002\/cam4.1387","volume":"7","author":"B Zhao","year":"2018","unstructured":"Zhao B, Zhang W, Yu D, Xu J, Wei Y. The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. Cancer Med. 2018;7(5):1642\u201359.","journal-title":"Cancer Med"},{"issue":"5","key":"4651_CR21","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","volume":"66","author":"ED Thompson","year":"2017","unstructured":"Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794\u2013801.","journal-title":"Gut"},{"issue":"4","key":"4651_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/ijc.25397","volume":"128","author":"F Shi","year":"2011","unstructured":"Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128(4):887\u201396.","journal-title":"Int J Cancer"},{"issue":"5","key":"4651_CR23","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.4049\/jimmunol.178.5.2714","volume":"178","author":"H Maier","year":"2007","unstructured":"Maier H, Isogawa M, Freeman GJ, Chisari FV. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol. 2007;178(5):2714\u201320.","journal-title":"J Immunol"},{"issue":"4","key":"4651_CR24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of Cancer. Immunity. 2018;48(4):812\u201330.","journal-title":"Immunity"},{"issue":"127","key":"4651_CR25","doi-asserted-by":"publisher","first-page":"127ra137","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra137.","journal-title":"Sci Transl Med"},{"issue":"3","key":"4651_CR26","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1172\/JCI36604","volume":"119","author":"D Franceschini","year":"2009","unstructured":"Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, Cerino A, Mondelli MU, Barnaba V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Investig. 2009;119(3):551\u201364.","journal-title":"J Clin Investig"},{"issue":"3","key":"4651_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nm.3485","volume":"20","author":"Y Liu","year":"2014","unstructured":"Liu Y, Carlsson R, Comabella M, Wang J, Kosicki M, Carrion B, Hasan M, Wu X, Montalban X, Dziegiel MH, et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med. 2014;20(3):272\u201382.","journal-title":"Nat Med"},{"issue":"11","key":"4651_CR28","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139\u201345.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4651-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4651-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4651-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T22:42:45Z","timestamp":1604702565000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4651-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4651"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4651-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,28]]},"assertion":[{"value":"27 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"766"}}